Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Takashi K. Kishimoto"'
Autor:
Alan Kivitz, Wesley DeHaan, Rehan Azeem, Justin Park, Sheri Rhodes, Jamie Inshaw, Sheldon S. Leung, Savvas Nicolaou, Lloyd Johnston, Takashi K. Kishimoto, Peter G. Traber, Earl Sands, Hyon Choi
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 825-847 (2023)
Abstract Introduction SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6 mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered wi
Externí odkaz:
https://doaj.org/article/cf6f1cb3ba274f37b044035ffe0ee7d4
Autor:
Nicholas D. Weber, Leticia Odriozola, Irene Ros-Gañán, Guillermo García-Porrero, David Salas, Josepmaria Argemi, Jean-Philippe Combal, Takashi K. Kishimoto, Gloria González-Aseguinolaza
Publikováno v:
JHEP Reports, Vol 5, Iss 5, Pp 100713- (2023)
Background & Aims: Gene therapy using recombinant adeno-associated virus (rAAV) vector carrying multidrug resistance protein 3 (MDR3) coding sequence (AAV8-MDR3) represents a potential curative treatment for progressive familial intrahepatic cholesta
Externí odkaz:
https://doaj.org/article/87de6a3ad3184e34980b1de9f40a5bae
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 13, Iss C, Pp 18-22 (2017)
A major obstacle to enzyme replacement therapy (ERT) with recombinant human acid-α-glucosidase (rhGAA) for Pompe disease is the development of high titers of anti-rhGAA antibodies in a subset of patients, which often leads to a loss of treatment eff
Externí odkaz:
https://doaj.org/article/6982ba32545843df92fdc44f63a5bdd2
Autor:
Robert A. LaMothe, Pallavi N. Kolte, Trinh Vo, Joseph D. Ferrari, Tracy C. Gelsinger, Jodie Wong, Victor T. Chan, Sinthia Ahmed, Aditi Srinivasan, Patrick Deitemeyer, Roberto A. Maldonado, Takashi K. Kishimoto
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
T cells reacting to self-components can promote tissue damage when escaping tolerogenic control mechanisms which may result in autoimmune disease. The current treatments for these disorders are not antigen (Ag) specific and can compromise host immuni
Externí odkaz:
https://doaj.org/article/41c70cd556174c1e9d6f0707d851f21d
Publikováno v:
ACS Chem Biol
Current treatments for unwanted antibody responses largely rely on immunosuppressive drugs compromising overall immunity. New approaches to achieve antigen-specific tolerance are desirable to avoid unwanted side effects. Several nanoparticle-based ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f485e547f43762fa51374eee1d35913e
https://doi.org/10.1021/acschembio.1c00212
https://doi.org/10.1021/acschembio.1c00212
Publikováno v:
Molecular Genetics and Metabolism Reports
Molecular Genetics and Metabolism Reports, Vol 13, Iss C, Pp 18-22 (2017)
Molecular Genetics and Metabolism Reports, Vol 13, Iss C, Pp 18-22 (2017)
A major obstacle to enzyme replacement therapy (ERT) with recombinant human acid-α-glucosidase (rhGAA) for Pompe disease is the development of high titers of anti-rhGAA antibodies in a subset of patients, which often leads to a loss of treatment eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef1346a14110b3e45d297ea3d63aea3e
https://pubmed.ncbi.nlm.nih.gov/28761815
https://pubmed.ncbi.nlm.nih.gov/28761815
Autor:
Timothy A. Springer, Donald E. Staunton, Michael L. Dustin, Angel L. Corbí, Richard S. Larson, Takashi K. Kishimoto
Publikováno v:
Advances in Immunology Volume 46 ISBN: 9780120224463
Publisher Summary This chapter focuses on the molecular biology of the leukocyte integrins, LFA-1, Mac-1, and p150,95, and on their role in mediating inflammation. Three recent developments have underscored the importance of the leukocyte integrins a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10fd873a08ceb4f3c44435f4a3dccbe6
https://ora.ox.ac.uk/objects/uuid:17ab44a5-1265-42b3-adc9-5ec866313155
https://ora.ox.ac.uk/objects/uuid:17ab44a5-1265-42b3-adc9-5ec866313155
Publikováno v:
Molecular Genetics and Metabolism. 120:S83-S84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::008a5005999bf2da683d72ab8ec43e7f
https://doi.org/10.1016/j.ymgme.2016.11.202
https://doi.org/10.1016/j.ymgme.2016.11.202
Autor:
Daniel Ferrari, Robert LaMothe, Pallavi Kolte, Aaron Griset, Conlin O’Neil, Thomas Leland, Fen-ni Fu, Nelly Viseux, Lloyd Johnston, Takashi K. Kishimoto, Roberto Maldonado
Publikováno v:
The Journal of Immunology. 200:55.44-55.44
We have shown that treatment with biodegradable tolerogenic nanoparticles carrying rapamycin (synthetic vaccine particles, SVP) and antigen (inside the particles or admixed) induces durable, antigen-specific immune tolerance even in the presence of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47e2d8c136cdcc9eaa624b9153c117cf
https://doi.org/10.4049/jimmunol.200.supp.55.44
https://doi.org/10.4049/jimmunol.200.supp.55.44